Brainshake is a Finnish biomedical company that claims to revolutionise blood testing. It tests for over 200 biomarkers opening a far broader window into the health state of an individual than existing blood tests. And despite beginning commercial operations just three years ago, it already has global ambitions and claims to be highly profitable – enough to secure €5m of primarily non-equity funding. We interviewed its CEO Teemu Suna.